Nevro Corp. has submitted a premarket approval supplement to the U.S. FDA seeking a green light for its Senza system to treat chronic pain associated with painful diabetic neuropathy (PDN). This ...
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback